Mowi ASA (MOWI)
Verdict history · MOWI
Every call Verdix has made on MOWI.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
See methodology for how verdicts are produced. Full track record →
The panel’s case for MOWI — and where they disagree.
The case for outweighs the case against at today's price.
OSL · Consumer Staples · 2026-08-01 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
The panel's take
Verdict: BUY · Conviction: HIGH · Last price: 202.6
The panel is structurally bullish: 6 voices are BUY (fundamental-scout, sentiment-scout, The Intrinsic-Value Modeler, The Asymmetric Bargainer, The Moat Compounder, The GARP Operator, The Forensic Skeptic), and the 2 cautious voices (technical-scout with WAIT, The Quality Rationalist with Neutral/Bullish lean) both object on PRICE/TIMING — they want a technical breakout above 209 or a cheaper entry, not because the business is broken. A BUY-vs-WAIT split where all caution is price/timing-driven does not synthesize to WAIT; it synthesizes to BUY because the net conviction on the business itself is strongly positive. The fundamental case is overwhelming: 10.3x trailing P/E with 19.5% ROE, PEG of 0.77, consensus 25-30% upside, and 6 of 6 fundamental voices confirm moat durability. HOLD would be wrong because there's no genuine business-level disagreement. WAIT would be wrong because the cautious camp's condition (weekly close above 209) is a tactical entry refinement, not a thesis requirement — the margin of safety at 202.60 is already adequate.
Key levels
Key levels · MOWI
NOK · as of 2026-08-01Analyst consensus target 202.6 NOK · range 202.6–202.6
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran Mowi ASA past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
The Intrinsic-Value ModelerValuation/DCF🟢 BullishMed
Signal: Mowi trades at 10.3x trailing P/E and 7.2x EV/EBITDA with a PEG of 0.77, classic levels for a cyclical bottom where the market has not priced in the 15% revenue recovery and margin expansion already underway. Conviction: Conviction is held back by dependence on salmon prices sustaining above €7.50/kg — a single contested macro assumption — though multiple independent confirmations (Q2 EBIT beat by 23%, record harvest volumes, falling feed costs, and Skretting's €55M annual savings from 2027) all point the same way.
The Asymmetric BargainerContrarian/Deep Value🟢 BullishMed
Signal: At 10.3x trailing P/E with a 19.5% ROE and 20% global market share, the downside to the ~170 NOK base low is capped at ~16% while the base case offers 18–30% upside and the bull case offers 50–100% over 3–5 years. Conviction: Conviction is elevated by the Dhandho 4/4 checklist passing cleanly: simple business, limited downside, substantial upside, and heavily favorable odds, with the gap between market perception of a risky commodity and the reality of a structurally-constrained industry leader providing multiple independent pillars for the thesis.
The Moat CompounderValue/Quality/Moat🟢 BullishHigh
Signal: Mowi's vertical integration, license-protected 20% global market share, and trailing P/E of 10.3 for a business with a durable competitive advantage present a wonderful business at a fair price with 15–18% upside to consensus fair value. Conviction: Conviction is tempered by the FCF margin of only 7.4% — one contested dependency on the capex normalization thesis — though the operational momentum from record Q2 harvest volumes, rising salmon prices, falling farming costs, and a positive weekly MACD creates a broad base of supporting evidence.
The GARP OperatorGrowth (GARP)🟢 BullishHigh
Signal: The PEG ratio of 0.77 — well below my 1.0 threshold — on 10.3x trailing earnings with 13%+ expected EPS growth makes this a textbook Stalwart trading at a discount, with the entire analyst community at zero sells and 29% upside to consensus. Conviction: Conviction is strong because the story is simple and repeatable (rising protein demand meets license-capped supply), the numbers are independently corroborated by 11 analysts with 9 Buys and 0 Sells, and the technical base-building above the 192 POC adds a non-fundamental confirmation layer.
The Forensic SkepticContrarian/Forensic🟢 BullishMed
Signal: The market is pricing Mowi on trailing depressed earnings when normalized EPS of €2.50–3.00 puts the true forward multiple at 8–9x, while hidden license assets carried at cost are worth multiples of book value, creating a 30–35% margin of safety. Conviction: Conviction is supported by multiple hard-to-dispute facts: zero accounting red flags, Q2 harvest beat of 150k tonnes, salmon prices up 12%, capex normalizing post-Nova Sea, and net debt/EBITDA declining to 1.9x — with the only unresolved dependency being whether the Norwegian resource rent tax regime stays stable or becomes punitive.
The Quality RationalistMental Models/Quality⚫ NeutralMed
Signal: Mowi has a real moat from licenses and vertical integration, but the 8.6% ROIC means this is a good business at a fair price, not a wonderful one — owner earnings are significantly less than reported earnings due to capital intensity, so I'd rather wait for a larger margin of safety. Conviction: Conviction is held back primarily by one contested structural assumption: that the biological risks and capital intensity don't fully offset the moat advantage, with the 19.7x P/FCF and NOK 37B net debt adding weight to the cautious side despite favorable cyclical timing.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All six fundamental archetypes agree Mowi possesses a genuine and durable economic moat — license restrictions, vertical integration, and 20% global market share create barriers to entry competitors cannot easily replicate.
- Every archetype acknowledges that salmon prices are recovering from a cyclical trough, costs are falling, and operational momentum is strong — Q2 2026 harvest beat expectations by 23% with record volumes.
- All archetypes recognize the current valuation (10.3x trailing P/E, 7.2x EV/EBITDA) represents a discount relative to Mowi's quality and normalized earnings power.
- There is unanimous agreement that the Norwegian resource rent tax is a real but already-priced-in headwind, not a thesis-breaking risk at current levels.
The real debate
- The Quality Rationalist sees an 8.6% ROIC that disqualifies Mowi from 'wonderful' status, while The Moat Compounder and The Asymmetric Bargainer see the 19.5% ROE and license-protected pricing power as sufficient evidence of a durable moat — the core disagreement is whether capital intensity or competitive advantage matters more for long-term compounding.
- The Quality Rationalist flags the overwhelming analyst consensus (zero sells, 85%+ buys) as a contrarian warning that the easy money may have been made, while The Forensic Skeptic argues this is not crowded euphoria because the stock remains below its 50-week EMA and is still base-building.
- The Intrinsic-Value Modeler and The Moat Compounder see adequate margin of safety at current prices (~15–18% upside to fair value), while The Quality Rationalist would only get interested on a 20% pullback — the tension is about how much discount a capital-intensive biological business requires.
The question it comes down to: Can Mowi's structural supply advantage and cost leadership generate enough free cash flow to justify a re-rating from cyclical commodity multiple (10x) to stable compounder multiple (14–18x), or does the capital intensity and biological risk permanently cap the valuation at current levels?
The bottom line
Watch the 209 NOK level on a weekly close with expanding volume — that is the 50% Fibonacci retracement and horizontal resistance confluence that, once broken, confirms the base breakout and removes the tactical timing objection. If salmon spot prices remain above €7.50/kg through Q4 2026, expect material upward earnings revisions that could push the stock toward the 240–245 consensus target range within 6–12 months. The key risk to monitor is not the resource rent tax (already priced in) but any biological event that forces harvest reductions across multiple quarters — a monthly close below 179.40 NOK would be the signal that the higher-low pattern has broken. The next operational catalyst is Q3 2026 results, where another harvest beat and continued cost declines would harden the recovery thesis; the Skretting feed cooperation savings of €55M annually starting in 2027 provide a dated margin catalyst independent of salmon prices. Net debt/EBITDA falling below 2.0x — expected by year-end 2026 — is the balance-sheet milestone that could trigger a dividend increase or buyback program, giving the stock a catalyst even if salmon prices flatline.
contact@verdixhq.com · Published 2026-08-01 · Prices as of 2026-08-01 · Time horizon: 3–12 months · Founder holds a direct position in MOWI · MOWI verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated